AI Investment Business

$140 Million Flowed into Dental AI Last Year

Dr Ali Vatan Ali Vatan
·

Venture capital poured over $140 million into dental AI in 2024. Is this the start of something real, or are we watching a bubble inflate?

$140 Million Flowed into Dental AI Last Year

Over $140 million in venture capital flowed into dental AI companies in 2024. I’m not an investor; I’m a dentist. But when that kind of money enters your profession in a single year, you pay attention.

Here’s where it went:

  • Pearl raised $58 million in a Series B round led by Left Lane Capital. They’re behind one of the first FDA-cleared dental AI systems.
  • Perceptive, backed by Mark Zuckerberg’s father Ed (himself a dentist), pulled in $30 million and completed the world’s first fully automated dental procedure on a human patient in Colombia.
  • VideaHealth continued building on earlier rounds, now sitting on roughly $70 million in cumulative investment.
  • Overjet, which closed a $53 million Series C in 2022, has accumulated over $130 million total.
  • LightSpun, a newer entrant focused on dental insurance administration, secured $13 million in Series A funding to automate claims processing.

According to CareQuest Innovation Partners, dental AI and machine learning startups secured approximately $145 million in 2024 alone, significantly higher than previous years. That’s not pocket money. That’s an industry being reshaped.

Genuine value mixed with hype

Some of these companies are building tools that will change how we practise. AI-assisted radiograph analysis is already showing real clinical promise. The ability to flag pathology that a tired clinician might miss on a Friday afternoon has tangible value.

But it’s very easy to be fooled by the magic of it. A computer that can seemingly think, that can look at an X-ray and highlight a periapical radiolucency: it feels like science fiction. When something feels like magic, money follows. Not all of that money is going to land well.

I’ve been around long enough to know that not every company riding this wave will survive. The dental AI space reminds me of the early aligner market. Everyone launched a clear aligner brand. Some were excellent. Some were, frankly, dangerous. The market sorted itself out, but not before patients were harmed and money was wasted.

The dust hasn’t settled

We’re in a transitional period. The technology is developing faster than regulation, faster than clinical evidence, and faster than most practitioners can keep up with.

That said, healthy competition is broadly a good thing. More companies means more options for clinicians, better products through competitive pressure, and eventually lower prices. When Pearl competes with Overjet, and Overjet competes with VideaHealth, we all benefit. Products get sharper, the evidence base grows, and the ones that don’t deliver real clinical value get weeded out.

Consolidation is coming. The market cannot sustain dozens of companies all doing variations of the same thing. We’ll see acquisitions, mergers, and some quiet disappearances over the next few years. The survivors will be those solving real clinical problems, not the ones with the flashiest demos.

What clinicians should do

If you’re a practising dentist, my advice is simple: stay curious but stay critical. Look at the evidence, not the marketing. Ask hard questions about validation studies, regulatory clearances, and what happens when the AI gets it wrong (because it will, sometimes).

Don’t be the last person to engage with this technology, but don’t bet your practice on a startup that might not exist in three years. There’s a sensible middle ground: keep your eyes open, read the literature, and wait for real-world data to accumulate.

The $140 million tells us serious people with serious money believe AI is the future of dentistry. They might be right. But believing something is the future and knowing what that future looks like are two very different things.

References